NEWS

  • Self vs non-self in avians and mammals

    Xenobiotic and pathogen recognition by the immune system relies on ability to discriminate self and non-self epitopes. Throughout their maturation process, antibodies are selected in a both positive and negative manner. This allows to trigger an immune response only against foreign substances such pathogens, not in the host organism. Mammals and avians are separated by nearly 300 000 000 years of evolution. Consequently, minor changes in genome sequences between mammals are reflected by high similarity in protein primary sequences, whereas the difference between mammalian and avian proteins is much more important. This difference also creates a wider gap between self and non-self when immunizing chicken against mammalian proteins. Thereby, generating and immune response and antibodies against a human protein is more likely to succeed in a different host (chicken) rather than a similar host (mouse or rabbit). The figure above illustrates this difference. This phylogenic diversity is one part of the explanation of why our antibodies work so well. See the data for yourself. Check out the antibodies. https://ibiosolutions.com/en/catalog/primary_antibodies/ View 3D-specific antibodies. http://info.ibiosolutions.com/gpcr Get your own antibody https://ibiosolutions.com/en/development-platform/

  • GPCRs targeted by antibodies raised against 3D epitopes

    Why target GPCRs with antibodies?

    The G Protein-coupled receptor (GPCR) superfamily represents the largest and single most important family of human drug targets. GPCRs play a central role in a plethora of biological processes, and are linked to a wide range of therapeutic areas including cancer, diabetes, inflammation, cardiovascular diseases, and chronic pain. Expressed in every type of cell in the body, GPCRs relay signals from outside the cell, across the membrane, to intracellular signalling pathways. The human genome encodes about 800 GPCRs, over half of these being olfactory or sensory receptors. More so, 370 GPCRs are actual or putative drug targets. Indeed, 20-30% of current prescription drugs modulate this class of proteins. For instance, 6 of the top 10 and 60 of the top 200 best-selling drugs in the US in 2010 target GPCRs. Thus, drugs targeting GPCR continue to generate annual multi-billion dollar sales. This unique antibody development platform has already yielded numerous candidates for the treatment of GI tract infections, inflammation, pain, colorectal cancer and breast cancer. In addition, Immune Biosolutions is actively advancing its new GPCR antibody lead series, as well as raising additional antibodies against relevant targets involved in a wide range of diseases.

    Challenges in raising GPCR antibodies

    Nevertheless, therapeutic targeting of GPCRs remains challenging, and novel biologics, such as antibodies, have yet to be approved. The discovery of effective therapeutic antibodies has been stymied by the lack of structural and mechanistic knowledge. This in turn, is linked to technical issues regarding GPCR production and purification with the necessity of maintaining native conformation during immunization. Progress has also been hampered by the limited intrinsic ability of current animal models such as rabbits, mice and camelids to produce high affinity antibodies against the highly conserved GPCR orthologs. Considering that antibodies provide higher specificity and lower clearance than small molecules, because of such critical issues, there is a scarcity of antibodies against GPCRs in the pre-clinical and clinical pipelines.

    How can GPCRs be targeted?

    Immune Biosolutions in collaboration with researchers from Université de Sherbrooke, has developed a new approach to therapeutic and diagnostic antibody discovery that tackles traditionally difficult targets such as GPCRs, integrins and ion channels. Fundamental limitations in commonly used strategies in antibody development for GPCRs and other membrane proteins which have repeatedly failed to deliver effective immunotherapies are now overcome with the proprietary Nebula platform.

    Key features of the Nebula platform

    Incremental custom antibody development platform.

    1- Proprietary design algorithm and synthesis of 3D-constrained peptides mimicking the target’s spatial conformation: For GPCRs, the peptides match the sequence and structure of extracellular loops (ECL). This allows to overcome immunization issues related to membrane-spanning GPCR expression and purification.

    2- Incremental chicken antibody generation: Antibodies are selected upon their ability to discriminate between self and non-self. And as mammalian proteins are conserved, their homology may be too high to trigger an immune response in mammalian hosts. Such issues are circumvented by the Nebula platform which taps into unexplored chicken repertoire and provides a new source of antibodies for discovery and human therapeutics.

    3- High-throughput selection and validation strategies with phage-display technologies: The best recombinant antibody candidates are identified and isolated in order to evaluate their functional and therapeutic potential.

    In short, the Nebula antibody platform enables a targeted shotgun approach relying on three-dimensional peptide design algorithms with phage-display selection strategies. At the core of the platform, is the chicken immune system which provides an untapped antibody repertoire. Chicken IgY antibodies are particularly effective when targeting highly conserved mammalian proteins such as GPCRs. These novel antibodies can be identified and fully humanized via the Nebula platform.

    Targeting GPCRs with antibodies

    Continually building on lessons learned with multiple GPCR targets, Immune Biosolutions through its Nebula platform can accelerate the discovery of novel antibody candidates for diagnostics and immunotherapy. Development of Immune Biosolutions’ Nebula antibody discovery platform was pioneered in 2012 by a team of young and innovative scientists. To accelerate the generation and identification of promising new antibody candidates, company co-founders Drs Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée tuned the platform into a robust therapeutic discovery engine integrating several unique technologies:

    • Antigen design algorithms
    • Three dimensional peptides
    • Proprietary immunostimulating adjuvants
    • Polyclonal IgY antibody purification
    • Recombinant chicken antibody technology

    Integrated in the Nebula platform, these technologies resolve current technical and scientific bottlenecks traditionally associated with generating GPCR-targeting antibodies. Go to case study.

    Addressing critical needs in the GPCR field

    Diseases related to the GPCR superfamily represent one of the largest global healthcare challenges and therefore one of the greatest medical needs. By 2018, revenues associated with GPCR therapeutic targeting are expected to exceed 110B$, and in the last decade, the emergence of biologics has yielded new diagnostics and treatment alternatives, and has provided better healthcare to millions of people worldwide. Immune Biosolutions is pioneering a new approach in design and discovery of therapeutic and diagnostic antibodies. These can serve for detection and modulation of GPCR superfamily members as well as other membrane proteins. The Nebula antibody development platform enables discovery of therapies for a wide range of disease by tackling the root causes, as well as by addressing the symptoms. The antibody candidates may be used as drugs and antibody-drug conjugates (ADC) with oral or intravenous administration, or as in vivo and ex vivo diagnostic tools. Immune Biosolutions is currently intensifying efforts on GI tract diseases and infections, oncology and pain/inflammation management, with future applications across multiple additional GPCR-related diseases.All with the promise of improving research and global health.

    Recombinant antibodies too

    Immune Biosolutions specializes in chicken antibody traditionally offered as polyclonal, but also in recombinant form. They're both great with any target including GPCRs. We can make antibodies to your dream target.

  • Immune Biosolutions selected for JLABS @ Toronto

    Immune Biosolutions selected for JLABS @ Toronto Immune Biosolutions is among the 22 growing businesses selected for JLABS @ Toronto. Initiated and managed by the pharmaceutical company Johnson & Johnson, JLABS are a network of 6 tech incubators focusing on life sciences. The newest facility, JLABS @ Toronto, located in the MaRS district, is the first located outside the US. JLABS resident companies Companies hosted in the state-of-the-art infrastructures of JLABS have access to J&J's scientific, operational and business resources. They can conclude partnerships together, but the companies maintain their independence towards Johnson & Johnson.Humanized IgY antibody Targeting GPCRs Immune Biosolutions was selected namely due to its proprietary antibody technologies allowing to generate antibodies against so far deemed difficult if not impossible targets. The latter include G protein-coupled receptors (GPCRs), flexible transmembrane proteins implicated in a wide variety of diseases. Despite a growing demand and the availability of several small molecules targeting GPCRs and modulating their activity, there is currently no GPCR-targeting therapeutic antibody in the clinic. This is mainly due to technical bottlenecks in conventional antibody generation. However, with the arrival of Immune Biosolutions at JLABS @ Toronto, this paradigm could rapidly change. To learn more Antibody development platform for difficult targets https://ibiosolutions.com/news/antibodies-that-target-gpcrs/ News wire http://www.newswire.ca/news-releases/johnson--johnson-innovation-opens-jlabs--toronto-578957501.html Johnson & Johnson press release http://jlabs.jnjinnovation.com/sites/www.jnjinnovation.com.jlabs/files/press/pr-2016.05.11-jlabs_toronto.pdf

  • Immune Biosolutions will continue its growth at EspaceLabz

    Immune Biosolutions, a JLABS @ Toronto resident, is pleased to announce the relocation of its Sherbrooke headquarters and laboratories in the new EspaceLabz center, located in the Sherbrooke’s Scientific Park. In addition to providing additional space, the new facility will grant access to state-of-the-art equipment to follow the increasing demand for Immune Biosolutions' Nebula Antibody Platform, and will allow additional R&D initiatives in the development of new life- saving technologies. This marks an important milestone for Immune Biosolutions. With recent and upcoming partnerships with key industry leaders and promising start-ups, we needed more space to support the growth and the future development of new therapeutic antibodies. -Frédéric Leduc, CEO Immune Biosolutions will enter its new facilities this summer, and EspaceLabz' official inauguration will take place in fall 2017. Read the complete press release. https://cdn2.hubspot.net/hubfs/471504/2017-03-22%20-%20iBio%20-Press%20release.pdf

4 Item(s)